Systemic Lupus Erythematosus

SYSTEMIC LUPUS ERYTHEMATOSUS

Voclosporin NDA for Lupus Nephritis Submitted to the FDA

The NDA for voclosporin has been submitted to the Food and Drug Administration (FDA) for the treatment for lupus nephritis.
Lesser Damage Accrual Among Patients Not Fulfilling the 2019 EULAR/ACR Criteria for SLE

Investigators determined the difference in outcomes in patients who achieved or did not achieve the 2019 EULAR/ACR criteria for SLE.
Hydroxychloroquine for SARS-CoV-2 Infection: How Did We Get Here?

Hydroxychloroquine is a less-toxic metabolite of the antimalarial drug chloroquine and is used as an immunomodulator for the treatment of autoimmune diseases.
Updated EULAR/ERA-EDTA Recommendations for the Management of Lupus Nephritis

The EULAR/ERA-EDTA developed updated recommendations for the management of lupus nephritis.
ACR Develops Clinical Guidance for the Management of Rheumatic Diseases During the COVID-19 Pandemic

The American College of Rheumatology developed clinical guidance for rheumatology providers for the management of rheumatic diseases during the COVID-19 pandemic.
Telitacicept Fast-Tracked for the Treatment of Systemic Lupus Erythematosus

The FDA has granted Fast Track designation to telitacicept for the treatment of systemic lupus erythematosus.
Risk for SLE in Patients With Idiopathic Thrombocytopenic Purpura

Patients with idiopathic thrombocytopenic purpura may have a higher risk of systemic lupus erythematosus and should be monitored for incidental lupus.
Low Frequency of Flares During and After Pregnancy in Patients With Inactive or Stable Lupus

Researchers identified predictors of flares during and after pregnancy in patients with inactive or stable disease activity and characterized and estimated the frequency of postpartum flares.
Assessing the Effect of ACC/AHA Hypertension Definition on Atherosclerotic Vascular Events in SLE

Researchers aimed to assess the effect of the 2017 American College ofCardiology/American Heart Association guidelines definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus.
ACR Recommendations for Hydroxychloroquine Management During the COVID-19 Pandemic

The American College of Rheumatology released guiding principles for the allocation, use, and management of hydroxychloroquine during the COVID-19 pandemic.

LATEST NEWS

Interferon Inhibition With Anifrolumab Reduces Disease Activity in Systemic Lupus Erythematosus

An investigational type 1 interferon receptor inhibitor was associated with significant reduction in disease activity in patients with systemic lupus erythematosus.

young girl, adolescent, head down, depression, mental health

High Serum Albumin Levels Have a Protective Effect on Mental Health in Patients With Juvenile SLE

Study findings from EULAR 2020 suggest that higher albumin levels provide a potentially protective effect on mental health in juvenile SLE.

Genetic Data May Increase Diagnostic Efficiency for Rheumatic Disease

Converting genotype information into an interpretable probability value for five different inflammatory arthritis-causing diseases could potentially improve the diagnostic efficiency of rheumatic disease.

Considerations for Hydroxychloroquine Use in Patients With Diabetes

Careful consideration should be taken before using hydroxychloroquine in patients with diabetes, particularly in the context of COVID-19.

WHO Suspends Testing of Hydroxychloroquine in Patients With COVID-19

The WHO has suspended use of the antimalarial drug hydroxychloroquine in a clinical trial of treatments of COVID-19 after a study revealed that patients taking the drug are at increased risk for death and serious heart problems.

Hydroxychloroquine Does Not Improve COVID-19 Pneumonia Outcomes

Hydroxychloroquine does not improve outcomes in COVID-19.

Ocular Complications Common Across Spectrum of Rheumatic Diseases

Between one-fifth and one-third of patients with rheumatoid arthritis, connective tissue disease, and vasculitis have ocular complications.

ACP Advises Against Chloroquine, Hydroxychloroquine Use for COVID-19

In a special article from the American College of Physicians, practice points are presented to guide the use of chloroquine or hydroxychloroquine in the setting of COVID-19.

PCT manifests when hepatic UROD activity is <20% of normal.1 As porphyrins accumulate in the liver, they are transported to the skin, leading to phototoxicity as light exposure causes the porphyrins to release photons.1 Subsequently, patients develop blisters on sun-exposed areas of their skin, particularly the hands, face, neck, and forearms. These areas are also prone to blisters and peeling after mild trauma. When the lesions scar, they may resemble systemic scleroderma. In some cases, lesions become painful. Patients may also have abnormal hair growth, skin thickening, and hypopigmentation. PCT is diagnosed when elevated porphyrins are detected in the plasma. Urine and fecal studies can confirm the diagnosis when they show similarly elevated porphyrin levels, with urine typically showing excess uroporphyrin and 7-carboxylate porphyrin and feces showing excess isocoproporphyrin.6 Patients with a PCT diagnosis should be tested for HCV if their status is unknown. Photo Credit: Dr Harout Tanielian/Science Source.

Sustained Virologic Response to HCV Therapy Does Not Decrease Incidence of SLE or RA

Patients with chronic hepatitis C (HCV) achieving sustained virologic response to pegylated interferon plus ribavirin therapy did not exhibit an effect on the incidence of systemic lupus erythematosus (SLE) or rheumatoid arthritis.

Chloroquine COVID-19 Trial Stopped After Patient Deaths

A study of chloroquine in novel coronavirus 2019 (COVID-19) patients was halted due to potentially deadly side effects.

Next post in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

LATEST NEWS

Want to read more?